Related Experiment Video
Updated: Jan 21, 2026

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
Published on: August 29, 2016
Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center
Praveena Iruku1, Martin Goros2, Jonathan Gelfond2
1Department of Hematology/Oncology, University of Colorado Health, Colorado Springs, CO, USA.
Introduction:
As cancer center funds are allocated toward several resources, clinical trial offices and the clinical trial infrastructure is constantly scrutinized. It has been shown that 20% of clinical trials fail to achieve their accrual goal and in an institutional level several trials are open with poor accrual. We sought to identify factors that are associated with clinical trial accrual and develop a model to predict clinical trial accrual.
Methods And Material:
We identified all clinical trials from 1999 to 2015 at UT Health Cancer Center San Antonio. We included observational as well as interventional clinical trials. We collected several variables such as type of study, type of malignancy, trial phase, PI of study.
Results:
In total we included 297 clinical trials. We identified several factors to be associated with clinical trial accrual (Sponsor type, trial phase, disease category, type of trial, disease state and whether the trial involved a new investigational agent). We developed a predictive model with an AUC of 0.65 that showed that observational, interventional, industry-sponsored trials and trials authored by the local PI were more likely to achieve their accrual goal.
Conclusion:
We were able to identify several factors that were significantly associated with clinical trial accrual. Based on these factors we developed a prediction model for clinical trial accrual. We believe that use of this model can help improve our cancer centers clinical trial portfolio and help in fund allocation.
Insights
Predicting clinical trial accrual is crucial for cancer centers. A new model identifies factors like sponsor type and trial phase, helping improve accrual rates and resource allocation.
Area of Science:
- Oncology
- Clinical Trial Management
- Biostatistics
Background:
- Cancer center funding necessitates efficient resource allocation, particularly for clinical trial infrastructure.
- A significant percentage of clinical trials (20%) fail to meet patient accrual targets, impacting research progress.
- Identifying factors influencing clinical trial accrual is essential for optimizing institutional performance.
Purpose of the Study:
- To identify key factors associated with clinical trial patient accrual.
- To develop a predictive model for clinical trial accrual at a cancer center.
Main Methods:
- A retrospective analysis of 297 clinical trials conducted between 1999 and 2015 at UT Health Cancer Center San Antonio.
- Inclusion of both observational and interventional studies, collecting data on study type, malignancy, trial phase, and principal investigator (PI).
Main Results:
- Several factors significantly correlated with clinical trial accrual, including sponsor type, trial phase, disease category, study type, disease state, and the use of new investigational agents.
- A predictive model achieved an Area Under the Curve (AUC) of 0.65.
- Observational, interventional, industry-sponsored trials, and those led by local PIs demonstrated higher likelihoods of meeting accrual goals.
Conclusions:
- Key factors influencing clinical trial accrual were successfully identified.
- A predictive model for clinical trial accrual was developed based on these identified factors.
- The model holds potential to enhance the cancer center's clinical trial portfolio and inform strategic fund allocation.
Related Concept Videos
Statistical Software for Data Analysis and Clinical Trials
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Design Example: Setting a Curve Using Design Data
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Cancer

